DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06608433

PIANO

CompletedPhase NA

Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function

Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function - the PIANO Study

Asset

Semaglutide

Oral · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

22

actual

Study population

Healthy volunteers

Key I/E criteria

•BMI 18.5-30•Male•Healthy volunteers

Primary endpoint

•Serum cortisol after Rybelsus

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06608433
Org study IDEKNZ2024-01744

Timeline

Milestones

Study first posted2024-09-23actual
Study start2025-01-16actual
Primary completion2025-10-31actual
Study completion2025-11-30actual
Last update posted2026-02-11actual

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years
Maximum age60 Years
SexMale
Healthy volunteersAccepted

Inclusion criteria

•Healthy male volunteers aged 18-60 years
•BMI 18.5-30 kg/m2
•No regular medication

Exclusion criteria

•participation in a trial with investigational drugs within 30 days
•vigorous physical exercise within 24 hours before the study participation
•alcohol intake within 24 hours before the study participation
•a history of intake of glucocorticoids or GLP-1 RA within the last 8 weeks.
•Known allergy towards GLP-1 RA

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Change in serum cortisol after Rybelsus vs. Placebo

Time frame:within 210 minutes after the intake of the study drug

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.